Research Update: Fighting COVID with Hyperbaric Oxygenation

Latest Research and UHMS CLINICAL TRIAL DESIGN AND RESEARCH PROTOCOL

Several studies are showing positive results when treating COVID patients with Hyperbaric Oxygenation.

Hyperbaric oxygen as an adjuvant treatment for patients with COVID-19 severe hypoxaemia: a randomised controlled trial.
Cannellotto M, et al., Emerg Med J. 2022 Feb;39(2):88-93. doi: 10.1136/emermed-2021-211253. Epub 2021 Dec 14.

Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention.
Tim Robbins, et al. Clin Med November 2021 https://doi.org/10.7861/clinmed.2021-0462

Hyperbaric oxygen therapy for patients with COVID-19.
John Kirby http://dx.doi.org/10.1136/emermed-2021-212015

Efficacy and safety of hyperbaric oxygen treatment in SARS-COV-2 (COVID-19) pneumonia: a systematic review.
Boet S, et al., Diving Hyperb Med. 2021 Sep 30;51(3):271-281. doi: 10.28920/dhm51.3.271-281.

Hyperbaric oxygen therapy in preventing mechanical ventilation in COVID-19 patients: a retrospective case series.
Thibodeaux K, et al., J Wound Care. 2020 May 1;29(Sup5a):S4-S8. doi: 10.12968/jowc.2020.29.Sup5a.S4.

The effects of hyperbaric oxygen therapy (HBOT) on coronavirus disease-2019 (COVID-19): a systematic review.
Oliaei S, et al., Eur J Med Res. 2021 Aug 19;26(1):96. doi: 10.1186/s40001-021-00570-2.

https://www.uhms.org/images/MiscDocs/Rational_and_study_design_for_treating_COVID_patients_with_HBO2.pdf

RATIONALE, STUDY DESIGN CONSIDERATIONS, AND PROTOCOL RECOMMENDATIONS FOR TREATING COVID-19 PATIENTS WITH HYPERBARIC OXYGEN

SUMMARY OF POTENTIAL MECHANISMS UNDERLYING COVID-19 PATIENT RESPONSES TO HBO2

“. . . . Patients with COVID-19 experience hypoxia, a profound inflammatory response, hypercoagulability, and may incur an oxygen debt. Hyperbaric oxygen may have an influence on all of these.

“A prominent feature of COVID-19 is hypoxia due to lung dysfunction. These patients are subject to severe hypoxemia and resultant tissue hypoxia. They can be exceedingly difficult to oxygenate in spite of high oxygen levels in their breathing mix and ventilatory support. The use of extracorporeal membrane oxygenation (ECMO) has not offered a noticeable advantage in this group of severely affected patients. Anecdotally, hyperbaric oxygen has been very successful in delivering adequate oxygen to COVID patients in the chamber. Many of these patients show persistent improvement after a hyperbaric treatment when returned to their ICU room. . . .

“Patients experiencing days of inadequate oxygenation may incur an oxygen debt. This is an additional insult related to but not identical to acute hypoxia. It has been observed in severe chronic anemia, CO poisoning, and even in sepsis. Van Meter has explained this phenomenon and reviewed the favorable effects of HBO2 in paying the oxygen debt. Untreated, oxygen debt is a major cause of multiorgan failure [40]. With the improvement in oxygenation that occurs, HBO2 therapy may pay the oxygen debt incurred during the patient’s severely hypoxic interval. The putative benefits of HBO2 for COVID-19 patients, therefore, include relief of hypoxia that persists after leaving the chamber, possible repayment of any accrued oxygen debt, reduced inflammation, and a possible improvement in hypercoagulation.” (For Full Report)

Multiple Countries and over a dozen U.S. Hospitals demonstrate effectiveness of HBOT in fighting COVID

https://local12.com/news/investigates/new-treatment-promises-hope-during-pandemic-cincinnati-duane-pohlman-coronavirus-covid

HBOT treatment promises hope during pandemic.

Duane Pohlman reports

From Louisiana to Long Island, hyperbaric chambers, once used only to treat divers suffering from the bends, are increasingly being used to treat COVID-19 patients with surprising success.

While the numbers are small, doctors at more than a dozen hospitals across the country say hyperbaric oxygen therapy (HBOT) is saving the lives of even the most critically ill coronavirus patients.

“The results thus far are pretty impressive,” Dr. Thomas Serena, founder and director of the SerenaGroup, a family of wound, hyperbaric and research companies, said in a recent interview.

At NYU Winthrop Hospital in Mineola, New York, Dr. Scott Gorenstein, the director of hyperbaric medicine, said, “I’m encouraged that hyperbaric oxygen could be a benefit.”

Dr. Paul Harch, the director of hyperbaric medicine at LSU in New Orleans and founder of HBOT.com, says HBOT appears to be working for most coronavirus cases. . . . (more)

The information provided by TreatNOW.org does not constitute a medical recommendation. It is intended for informational purposes only, and no claims, either real or implied, are being made.